ESR1 and breast carcinoma: However, approximately 30–40% of ER + breast cancer patients receiving adjuvant tamoxifen therapy still would relapse or progress to deadly advanced metastatic stages within 15 years follow-up; this is largely attributed to tamoxifen resistance (Ye et al., 2019).